J05AE10 • darunavir • Antiinfectives for systemic use | Direct acting antivirals | Protease inhibitors
Darunavir is a protease inhibitor used for the treatment of human immunodeficiency virus (HIV) infection. It works by inhibiting the HIV protease enzyme, which is essential for viral replication, thereby reducing the viral load.
The medication is taken orally, usually once daily, in combination with other antiretroviral drugs. Common side effects include nausea, diarrhea, headaches, and skin rashes.
Darunavir is contraindicated in patients with hypersensitivity to the active substance or any of its excipients. It should also be used with caution in patients with severe hepatic conditions.
This medication is an important option for managing HIV infection, helping to improve patients' quality of life and prevent disease progression.
Substance: darunavir
Date of last drug list: 01-08-2023
Commercial code: W63666001
Concentration: 800mg
Pharmaceutical form: film-coated tablets
Quantity: 30
Product type: generic
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: ALVOGEN MALTA OPERATIONS (ROW) LIMITED - MALTA
Holder: ALVOGEN MALTA OPERATIONS (ROW) LIMITED - MALTA
Number: 9881/2017/01
Shelf life: 30 months-after packing for marketing;after the first opening of the bottle-6 months